SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis

Hodges, Gethin W.; Bang, Casper N.; Eugen‐Olsen, Jesper; Olsen, Michael Hecht; Boman, Kurt; Ray, Simon; Gohlke-Bärwolf, Christa; Kesäniemi, Y. Antero; Jeppesen, Jørgen; Wachtell, Kristian

doi:10.1016/j.cjca.2016.04.012

Cited by 12 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-lowering treatment and suPAR 4 Conclusions: Simvastatin and Ezetimibe treatment impeded the progression of the timerelated increase in plasma suPAR levels. Year-1 suPAR was associated with all-cause mortality, MCE, and AVE irrespective of baseline levels (SEAS study: NCT00092677).…”

Section: Accepted Manuscriptmentioning

confidence: 98%

Effect of simvastatin and ezetimibe on suPAR levels and outcomes

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Accepted Manuscriptmentioning

confidence: 98%

Effect of simvastatin and ezetimibe on suPAR levels and outcomes

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…suPAR was also useful in the evaluation of patients with ischemic or dilative cardiomyopathy [36]. It retained its prognostic value in patients with AS (SEAS study) [42]; and in a retrospective analysis suPAR plasma levels were elevated in patients with STEMI [15]. In patients who presented in cardiac arrest it was shown in a pilot study that suPAR elevation after hypothermia induction was a predictor of mortality [40], while results from a pre-determined sub-study of the prospective FINNRESUSCI study showed that elevated suPAR levels were associated with poor outcome in out-of-hospital cardiac arrest in ICU patients, and that suPAR alone had inadequate predictive value for poor outcome [41].…”

Section: Discussionmentioning

confidence: 99%

“…Given that suPAR has been utilized as a CHF biomarker, it is not unexpected to evaluate it in aortic valve disease, which comprises the majority of symptomatic valvulopathies and is an important cause of CHF. One study investigated the prognostic value of suPAR in asymptomatic patients with aortic stenosis (AS) [42]. suPAR measurements were available for 1,503 patients enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study cohort.…”

Section: Supar In the Evaluation Of Aortic Valve Diseasementioning

confidence: 99%

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease

et al. 2021

View full text Add to dashboard Cite

This review summarizes the published literature referring to the use and validity of the biomarker soluble urokinase plasminogen activator receptor (suPAR) when used for the assessment of patients with cardiac diseases. It is measured by enzyme-linked immunosorbent assay (ELISA) in plasma samples. In cardiology a cutoff value range of 3.5-4.5 ng/mL has been commonly utilized. Different cutoff values may be applied based on the measuring kit used, the patient population and the clinical setting. A PubMed/Medline search was conducted aiming to identify all publications relevant to the use of suPAR in patients with cardiac diseases. A total of 39 studies were included in this review. suPAR as a marker of inflammation has been used more extensively in recent years, alone or in combination with other biomarkers of inflammation and cardiac pathology in the assessment of patients with acute and chronic cardiac diseases. suPAR is closely related to the pathophysiology of cardiac disease, and a number of publications encourages its use as a valuable biomarker in the assessment of patients presenting to the cardiology service. It may be most valuable in the risk assessment of patients with acute coronary syndromes and congestive heart failure, as suPAR elevation may be an independent predictor of mortality in these conditions. In conclusion, among several biomarkers used for clinical entities with underlying inflammatory pathophysiology including cardiac diseases, suPAR is a novel attractive index for the prognostic risk stratification of cardiac patients. More research is warranted to confirm its diagnostic and prognostic validity, alone or combined with other cardiac and inflammatory biomarkers.

show abstract

“…We and others have previously reported that elevated suPAR levels are associated with cardiovascular risk factors, subclinical and clinical cardiovascular disease including CAD, adverse cardiovascular outcomes and progression of chronic kidney disease [7,16-18,8,9,19-26]. Higher plasma and intra-plaque suPAR levels were noted to be associated with symptomatic carotid stenosis and vulnerable plaques [10].…”

Section: Discussionmentioning

confidence: 99%

Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes

et al. 2017

View full text Add to dashboard Cite

Background and aims Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study. Methods SuPAR levels were measured in 5810 patients (mean age 63 years, 63% male, 77% with obstructive coronary artery disease [CAD]) undergoing cardiac catheterization. The presence of PAD (n = 967, 17%) was classified as carotid (36%), lower/upper extremities (30%), aortic (15%) and multisite disease (19%). Multivariable logistic and Cox regression models were used to determine independent predictors of prevalent PAD and outcomes including all-cause death, cardiovascular death and PAD-related events after adjustment for age, gender, race, body mass index, smoking, diabetes, hypertension, hyperlipidemia, renal function, heart failure history, and obstructive CAD. Results Plasma suPAR levels were 22.5% (p < 0.001) higher in patients with PAD compared to those without PAD. Plasma suPAR was higher in patients with more extensive PAD (≥2 compared to single site) p < 0.001. After multivariable adjustment, suPAR was associated with prevalent PAD; odds ratio (OR) for highest compared to lowest tertile of 2.0, 95% CI (1.6–2.5) p < 0.001. In Cox survival analyses adjusted for clinical characteristics and medication regimen, suPAR (in the highest vs. lowest tertile) remained an independent predictor of all-cause death [HR 3.1, 95% CI (1.9–5.3)], cardiovascular death [HR 3.5, 95% CI (1.8–7.0)] and PAD-related events [HR = 1.8, 95% CI (1.3–2.6) p < 0.001 for all]. Conclusions Plasma suPAR level is predictive of prevalent PAD and of incident cardiovascular and PAD-related events. Whether SuPAR measurement can help screen, risk stratify, or monitor therapeutic responses in PAD requires further investigation.

show abstract

SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis

Cited by 12 publications

References 16 publications

Effect of simvastatin and ezetimibe on suPAR levels and outcomes

Effect of simvastatin and ezetimibe on suPAR levels and outcomes

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease

Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes

Contact Info

Product

Resources

About